These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 10903191

  • 41. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-Hübner C, Hokken-Koelega AC, KIGS Steering Committee.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1702-1711. PubMed ID: 28323917
    [Abstract] [Full Text] [Related]

  • 42. Growth response and final height in growth hormone-deficient patients treated with biosynthetic growth hormone.
    Chen YD, Shu SG, Chi CS.
    Acta Paediatr Taiwan; 2001 May 01; 42(5):291-6. PubMed ID: 11729706
    [Abstract] [Full Text] [Related]

  • 43. Intermittent treatment with human growth hormone (GH) in isolated GH deficiency and in multiple pituitary hormone deficiencies.
    Pertzelan A, Kauli R, Assa S, Greenberg D, Laron Z.
    Clin Endocrinol (Oxf); 1976 Jan 01; 5(1):15-24. PubMed ID: 1248156
    [Abstract] [Full Text] [Related]

  • 44. Clinical trial with somatonorm in idiopathic growth hormone deficiency in children.
    Shi YF, Liu R, Bao XL, Deng JY, Gunnarsson R.
    Chin Med J (Engl); 1990 Jun 01; 103(6):470-7. PubMed ID: 2119959
    [Abstract] [Full Text] [Related]

  • 45. Regular fluctuations in growth hormone (GH) release determine normal human growth.
    Gill MS, Thalange NK, Foster PJ, Tillmann V, Price DA, Diggle PJ, Clayton PE.
    Growth Horm IGF Res; 1999 Apr 01; 9(2):114-22. PubMed ID: 10373344
    [Abstract] [Full Text] [Related]

  • 46. [New findings and the potential use of the growth hormone].
    Sotos JF.
    An Esp Pediatr; 1992 Jun 01; 36 Suppl 48():166-9. PubMed ID: 1636958
    [Abstract] [Full Text] [Related]

  • 47. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2013 Oct 01; 98(10):4013-22. PubMed ID: 24001750
    [Abstract] [Full Text] [Related]

  • 48. The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood.
    Butler JV, Whittington JE, Holland AJ, McAllister CJ, Goldstone AP.
    Dev Med Child Neurol; 2010 Jun 01; 52(6):e88-93. PubMed ID: 20041936
    [Abstract] [Full Text] [Related]

  • 49. Growth hormone treatment of patients with Prader-Willi syndrome. Swedish Growth Hormone Advisory Group.
    Ritzén EM, Lindgren AC, Hagenäs L, Marcus C, Müller J, Blichfeldt S.
    J Pediatr Endocrinol Metab; 1999 Apr 01; 12 Suppl 1():345-9. PubMed ID: 10698600
    [Abstract] [Full Text] [Related]

  • 50. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH, Kuppens RJ, Bakker NE, van Alfen-van der Velden JAEM, Hokken-Koelega ACS.
    Clin Endocrinol (Oxf); 2018 Jun 01; 88(6):806-812. PubMed ID: 29418016
    [Abstract] [Full Text] [Related]

  • 51. Final height of patients with classical congenital adrenal hyperplasia.
    Aycan Z, Akbuğa S, Cetinkaya E, Ocal G, Berberoğlu M, Evliyaoğlu O, Adiyaman P.
    Turk J Pediatr; 2009 Jun 01; 51(6):539-44. PubMed ID: 20196386
    [Abstract] [Full Text] [Related]

  • 52. [Body height in children with growth hormone deficiency: results following 5-l5 years of treatment].
    Tanner JM.
    Z Gesamte Inn Med; 1988 Aug 01; 43(15):408-11. PubMed ID: 3176581
    [Abstract] [Full Text] [Related]

  • 53. Final height and pubertal development in children with growth hormone deficiency after long-term treatment.
    Frisch H, Birnbacher R.
    Horm Res; 1995 Aug 01; 43(4):132-4. PubMed ID: 7750913
    [Abstract] [Full Text] [Related]

  • 54. Treatment of hypopituitarism with recombinant somatropin for 1 year.
    Takano K, Shizume K, Hibi I, Okuno A, Hanyu K, Suwa S, Nakajima H, Kondo T, Kato K, Iwatani N.
    Acta Paediatr Scand Suppl; 1988 Aug 01; 347():169-75. PubMed ID: 3254031
    [Abstract] [Full Text] [Related]

  • 55. Growth hormone treatment in Léri-Weill syndrome.
    Thuestad IJ, Ivarsson SA, Nilsson KO, Wattsgård C.
    J Pediatr Endocrinol Metab; 1996 Aug 01; 9(2):201-4. PubMed ID: 8887145
    [Abstract] [Full Text] [Related]

  • 56. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
    Oto Y, Tanaka Y, Abe Y, Obata K, Tsuchiya T, Yoshino A, Murakami N, Nagai T.
    Am J Med Genet A; 2014 Mar 01; 164A(3):671-5. PubMed ID: 24443368
    [Abstract] [Full Text] [Related]

  • 57. Impaired GH secretion in patients with SHOX deficiency and efficacy of recombinant human GH therapy.
    Iughetti L, Vannelli S, Street ME, Pirazzoli P, Bertelloni S, Radetti G, Capone L, Stasiowska B, Mazzanti L, Gastaldi R, Maggio MC, Predieri B.
    Horm Res Paediatr; 2012 Mar 01; 78(5-6):279-87. PubMed ID: 23208451
    [Abstract] [Full Text] [Related]

  • 58. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R, Tubau C, Calvo L, Brun C, Capdevila N, Larramona H, Gabau E.
    J Pediatr Endocrinol Metab; 2019 Aug 27; 32(8):879-884. PubMed ID: 31271556
    [Abstract] [Full Text] [Related]

  • 59. Effects of growth hormone treatment on height, weight, and obesity in Taiwanese patients with Prader-Willi syndrome.
    Lin HY, Lin SP, Tsai LP, Chao MC, Chen MR, Chuang CK, Huang CY, Tsai FJ, Chou IC, Chiu PC, Huang CH, Yen JL, Lin JL, Kuo PL.
    J Chin Med Assoc; 2008 Jun 27; 71(6):305-9. PubMed ID: 18567561
    [Abstract] [Full Text] [Related]

  • 60. Growth hormone (GH) treatment up-regulates GH receptor mRNA levels in adipocytes from patients with GH deficiency and Prader-Willi syndrome.
    Kamel A, Margery V, Norstedt G, Thorén M, Lindgren AC, Brönnegård M, Marcus C.
    Pediatr Res; 1995 Sep 27; 38(3):418-21. PubMed ID: 7494669
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.